Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan

Table 5 Odds ratio and 95%CI of APE1 haplotypes for colorectal cancer stratified by sex, age at diagnosis, and tumor site and stage

	APE1 Asp148Glu/T-656G
	Asp/T		Asp/G		Glu/T		Glu/G
	Ca/Co (%)1	OR (95%CI)2	Ca/Co (%)1	OR (95%CI)2	Ca/Co (%)1	OR (95%CI)2	Ca/Co (%)1	OR (95%CI)2
All	41.1/41.5	1.00 (ref)	16.3/17.7	0.93 (0.75-1.15)	14.5/13.4	1.09 (0.87-1.37)	28.1/27.5	1.03 (0.86-1.24)
Gender
Male	42.5/40.0	1.00 (ref)	16.0/16.8	0.87 (0.66-1.16)	14.5/14.6	0.91 (0.67-1.22)	27.1/29.7	0.84 (0.66-1.06)
Female	39.3/44.6	1.00 (ref)	16.7/18.9	1.00 (0.73-1.36)	14.5/11.8	1.39 (0.98-1.97)	29.5/24.7	1.36 (1.03-1.78)a
Age at diagnosis (yr)
≤ 60	42.1/42.7	1.00 (ref)	17.1/17.2	1.01 (0.74-1.38)	15.7/14.8	1.08 (0.77-1.50)	25.0/25.3	1.00 (0.76-1.32)
> 60	40.3/40.5	1.00 (ref)	15.6/18.1	0.87 (0.65-1.15)	13.5/12.3	1.10 (0.81-1.50)	30.6/29.1	1.06 (0.84-1.34)
Tumor site
Colon	40.4/41.5	1.00 (ref)	16.7/17.7	0.96 (0.74-1.25)	15.5/13.4	1.20 (0.91-1.58)	27.4/27.5	1.03 (0.82-1.28)
Rectum	41.7/41.5	1.00 (ref)	16.0/17.7	0.90 (0.69-1.16)	13.5/13.4	0.99 (0.75-1.31)	28.8/27.5	1.04 (0.84-1.29)
Stage
0, I, II	41.1/41.5	1.00 (ref)	15.8/17.7	0.90 (0.69-1.17)	14.9/13.4	1.14 (0.86-1.51)	28.2/27.5	1.02 (0.82-1.28)
III, IV	41.1/41.5	1.00 (ref)	16.7/17.7	0.95 (0.74-1.23)	14.1/13.4	1.06 (0.81-1.39)	28.1/27.5	1.04 (0.84-1.29)

¹Percentage of cases/percentage of controls;

²Adjustment for age and sex (except in gender stratification, where only sex was adjusted for). The

^aP < 0.05 is the comparison between CRC cases and controls among female in calculating OR for Glu/G haplotype vs Asp/T haplotype.